Reported 2 days ago
BofA has raised its price target for Merus (NASDAQ:MRUS) from $70 to $92 while maintaining a Buy rating following positive Phase 2 trial results for a treatment involving petosemtamab and pembrolizumab in head and neck squamous cell carcinoma. The trial achieved a 79% objective survival rate and a 63% overall response rate, suggesting potential for this combination therapy to be considered best-in-class for HNSCC patients.
Source: YAHOO